You are here: Home: MGU Audio Programs: MGU 1 | 2008 Audio: MGU 1 | 2008
 
 
  Go to interview with James J Vredenburgh, MD
Go to interview with Henry S Friedman, MD
Go to interview with Jeffrey Raizer, MD
Go to interview with Lauren E Abrey, MD
 


To listen to individual tracks, click on the track you wish to listen to.
To download tracks, right-click on the one you wish to download.
     
James J Vredenburgh, MD
Professor of Medicine
Preston Robert Tisch
Brain Tumor Center
Duke University Medical Center
Durham, North Carolina
  
  Click here to download the entire interview  
Track 1 Key molecular pathways involved in the development of malignant gliomas
Track 2 Imatinib with hydroxyurea in secondary glioblastoma multiforme (GBM)
Track 3 Evaluating response to treatments for GBM
Track 4 Targeting the EGFR pathway in the treatment of malignant gliomas
Track 5 Role of testing for EGFRvIII mutation and PTEN status in decision-making regarding the use of EGFR tyrosine kinase inhibitors
Track 6 Targeting the VEGF pathway with bevacizumab in the treatment of GBM

Track 7 Bevacizumab with irinotecan in recurrent GBM
Track 8 Oral VEGF tyrosine kinase inhibitor cediranib
Track 9 Side effects and toxicity of bevacizumab in the treatment of GBM
Track 10 Risk of bleeding with bevacizumab in the treatment of primary or metastatic CNS tumors
Track 11 Incidence, management and potential mechanism of bevacizumab-associated fatigue
Track 12 Perspective on the improvements in rate and duration of response with bevacizumab/irinotecan compared to conventional therapies
Track 13 Efficacy and safety of single-agent cediranib
Track 14 Novel agents targeting the VEGF pathway
Track 15 Ongoing clinical trial evaluating cediranib
Track 16 Bevacizumab in combination with other agents in recurrent GBM
Track 17 Clinical use of Gliadel® (carmustine-impregnated) wafers for GBM
Track 18 Multidisciplinary approach to the management of brain tumors
Track 19 End-of-life care for patients with malignant gliomas
Track 20 Etiology and pathophysiology of brain tumors
Track 21 Treatment algorithm for patients with newly diagnosed or recurrent GBM
Track 22 Continuation of bevacizumab upon disease progression
Track 23 Treatment for patients with GBM in the community setting
Track 24 Referring patients to tertiary centers for neurosurgery
Track 25 Ongoing clinical trials for patients with malignant gliomas
     
Orlowski, MD, PhD Henry S Friedman, MD
James B Powell Jr Professor
of Neuro-Oncology
Deputy Director, The Preston Robert
Tisch Brain Tumor Center
Duke University Medical Center
Durham, North Carolina
  
  Click here to download the entire interview  
Track 1 Differences between neurology and oncology management of malignant gliomas
Track 2 Ongoing clinical trials for patients with malignant gliomas
Track 3 Management of malignant gliomas in clinical practice
Track 4 Bevacizumab in the management of GBM
Track 5 Bevacizumab in combination with irinotecan or temozolomide
Track 6 Clinical use of bevacizumab as front-line therapy
Track 7 Clinical use of bevacizumab for patients with brain metastases

Track 8 Clinical use of neoadjuvant therapy
Track 9 Neuradiab: A radiolabeled antitenascin monoclonal antibody
Track 10 Comparison of carmustine wafers and Neuradiab
Track 11 Clinical use of carmustine wafers
Track 12 Quality of neurosurgery in the US
Track 13 Clinical implications of EGFRvIII mutations
Track 14 Clinical use of erlotinib in GBM
Track 15 Cediranib and novel biologics for GBM
Track 16 Imaging studies to assess response to novel agents
Track 17 Long-term survival among patients with GBM
     
Jeffrey Raizer, MD
Director, Medical Neuro-Oncology
Robert H Lurie Comprehensive
Cancer Center
Northwestern University
Feinberg School of Medicine
Chicago, Illinois		  
  Click here to download the entire interview  
Track 1 Carmustine wafers and temozolomide for malignant gliomas
Track 2 Duration of therapy with temozolomide
Track 3 Adjuvant radiation therapy with or without temozolomide for glioblastoma
Track 4 Targeted therapies for malignant gliomas
Track 5 Anti-angiogenic strategies in the management of malignant gliomas
Track 6 Phase II study of bevacizumab in patients with multiple recurrent or progressive malignant gliomas

Track 7 Predictors of response to bevacizumab
Track 8 Clinical experience with single-agent bevacizumab
Track 9 Clinical use of bevacizumab in patients with malignant gliomas
Track 10 Tolerability of bevacizumab in patients with malignant gliomas
Track 11 Targeted agents being investigated in malignant gliomas
Track 12 Future trials for malignant gliomas

Track 13 Local therapies and imaging studies for malignant gliomas
Track 14 Case discussion: A 55-year-old woman with a left frontal glioblastoma

     
Lauren E Abrey, MD
Vice Chairman and Director
of Clinical Research
Department of Neurology, Memorial
Sloan-Kettering Cancer Center
New York, New York		  
  Click here to download the entire interview  
Track 1 Trials of bevacizumab with radiation therapy
Track 2 Key molecular pathways in malignant gliomas
Track 3 Primary CNS lymphomas
Track 4 Temozolomide in combination with radiation therapy
Track 5 Adding bevacizumab to radiation therapy and temozolomide
Track 6 Imaging studies for patients with malignant gliomas

Track 7 Supportive care issues for patients with malignant gliomas
Track 8 Community-based care for patients with malignant gliomas
Track 9 Quality of neurosurgery in patients with malignant gliomas